A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients

Matsubara, Keita; Morozumi, Miyuki; Okada, Takemichi; Matsushima, Takahiro; Komiyama, Osamu; Shoji, Michi; Ebihara, Takashi; Ubukata, Kimiko; Sato, Yoshitake; Akita, Hironobu; Sunakawa, Keisuke; Iwata, Satoshi

doi:10.1007/s10156-009-0715-7

Cited by 107 publications

(104 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2 Of the 4943 total citations reviewed, 16 met criteria for inclusion in the qualitative synthesis. 5,12,13,16,17,[20][21][22][23][24][25][26][27][28][29][30] One RCT 20 used different outcome metrics at 2 different times and, for the purposes of this review, was considered 2 separate RCTs. Therefore, 17 studies were included.…”

Section: Resultsmentioning

confidence: 99%

“…Therefore, 17 studies were included. Four citations were non-English and were translated by the review authors (2 in Spanish, 23 20,22,27,28 or enabled the review authors (E.B. and R.M.)…”

Section: Resultsmentioning

confidence: 99%

“…30 Ten RCTs 12 10 One study did not report the total number of pediatric patients. 17 Studies used various combinations of methods for M. pneumoniae detection; 5 used culture of nasopharyngeal specimens, 17,23,24,27,28 15 used serology, 5,12,13,16,17,[20][21][22][23][24][25][26][28][29][30] and 6 used polymerase chain reaction assays of upper airway specimens. 12,20,23,25,26,28 No trials were placebo controlled, and a number of studies received pharmaceutical company funding.…”

Section: Resultsmentioning

confidence: 99%

“…Pediatric CA-LRTI Secondary to M. pneumoniae Nine studies 5,13,16,20,22,23,27,28 provided enough detail to allow a comparison of M. pneumoniae spectrum and nonspectrum treatment in pediatric patients with CA-LRTI secondary to M. pneumoniae and included a total of 723 such patients (Table 4). In terms of overall clinical improvement, 4 of 5 RCTs found no clinical benefit.…”

Section: Spectrum-specific Treatment Inmentioning

confidence: 99%

“…5 One retrospective case-control study found an overall clinical benefit and 2 other studies identified a decrease in fever duration, although these were rated as being among the lowest quality of evidence in this review. 22,27,28 Esposito et al 2o (study A) was the only RCT to identify a clinical benefit, but the patient population included children with URTI. Additionally, the data were categorized only as "atypical" bacteria and did not separate C. pneumoniae from M. pneumoniae.…”

Section: Figurementioning

confidence: 99%

See 4 more Smart Citations

Treatment of Mycoplasma Pneumonia: A Systematic Review

et al. 2014

View full text Add to dashboard Cite

BACKGROUND AND OBJECTIVE: Children with community-acquired lower respiratory tract infection (CA-LRTI) commonly receive antibiotics for Mycoplasma pneumoniae. The objective was to evaluate the effect of treating M. pneumoniae in children with CA-LRTI.METHODS: PubMed, Cochrane Central Register of Controlled Trials, and bibliography review. A search was conducted by using Medical Subject Headings terms related to CA-LRTI and M. pneumoniae and was not restricted by language. Eligible studies included randomized controlled trials (RCTs) and observational studies of children #17 years old with confirmed M. pneumoniae and a diagnosis of CA-LRTI; each must have also compared treatment regimens with and without spectrum of activity against M. pneumoniae. Data extraction and quality assessment were completed independently by multiple reviewers before arriving at a consensus. Data were pooled using a random effects model. RESULTS:Sixteen articles detailing 17 studies were included. The most commonly selected primary outcome was symptomatic improvement. Nine studies examined M. pneumoniae treatment in CA-LRTI secondary to M. pneumoniae, and 5 RCTs met criteria for meta-analysis. The suggested pooled risk difference of 0.12 (95% confidence interval, 20.04 to 0.20) favoring treatment was not significantly different and demonstrated significant heterogeneity. Limitations included substantial bias and subjective outcomes within the individual studies, difficulty interpreting testing modalities, and the inability to correct for mixed infections or timing of intervention. CONCLUSIONS:We identified insufficient evidence to support or refute treatment of M. pneumoniae in CA-LRTI. These data highlight the need for well-designed, prospective RCTs assessing the effect of treating M. pneumoniae in CA-LRTI.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Therefore, 17 studies were included. Four citations were non-English and were translated by the review authors (2 in Spanish, 23 20,22,27,28 or enabled the review authors (E.B. and R.M.)…”

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Spectrum-specific Treatment Inmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 3 more Smart Citations

Treatment of Mycoplasma Pneumonia: A Systematic Review

et al. 2014

View full text Add to dashboard Cite

show abstract

Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections

et al. 2022

View full text Add to dashboard Cite

Key Points Question What are the temporal and regional trends in the proportion of macrolide-resistant Mycoplasma pneumoniae (MRMP) infections? Findings In this systematic review and meta-analysis of 150 articles including 27 408 samples, the proportion of MRMP infections differed in temporal trends and variant types according to geographical region. The proportion of MRMP infections was highest in the Western Pacific regions, followed by the Southeast Asian region, the region of the Americas, and the European region. Meaning This study suggests that prevention efforts are needed to decrease MRMP disease burden.

show abstract

Mycoplasma pneumoniae infection: Basics

Saraya

2017

J of Gen and Family Med

View full text Add to dashboard Cite

Mycoplasma pneumoniae (Mp) is one of the leading causes of community‐acquired pneumonia and can cause a number of extrapulmonary manifestations in the absence of pneumonia. In this regard, primary care physicians should know how to suspect, diagnose, and manage patients with Mp infection. This review gives a general overview of the basic clinical aspects of Mp infection with special reference to pneumonia, which will help further understanding of the disease.

show abstract

A comparative clinical study of macrolide-sensitive and macrolide-resistant Mycoplasma pneumoniae infections in pediatric patients

Cited by 107 publications

References 8 publications

Treatment of Mycoplasma Pneumonia: A Systematic Review

Treatment of Mycoplasma Pneumonia: A Systematic Review

Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections

Mycoplasma pneumoniae infection: Basics

Contact Info

Product

Resources

About